DAWN [NASD]
Day One Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.01 Insider Own1.80% Shs Outstand58.38M Perf Week5.10%
Market Cap1.21B Forward P/E- EPS next Y-2.11 Insider Trans218.84% Shs Float18.50M Perf Month197.74%
Income-183.20M PEG- EPS next Q-0.49 Inst Own71.80% Short Float28.26% Perf Quarter87.72%
Sales- P/S- EPS this Y-587.70% Inst Trans3.66% Short Ratio3.35 Perf Half Y7.20%
Book/sh4.45 P/B3.85 EPS next Y16.40% ROA-62.20% Target Price37.50 Perf Year-15.12%
Cash/sh3.72 P/C4.60 EPS next 5Y- ROE-63.70% 52W Range5.44 - 28.70 Perf YTD1.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.35% Beta-
Dividend %- Quick Ratio32.70 Sales past 5Y- Gross Margin- 52W Low214.71% ATR1.31
Employees42 Current Ratio32.70 Sales Q/Q- Oper. Margin- RSI (14)74.78 Volatility7.09% 10.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-88.90% Profit Margin- Rel Volume0.64 Prev Close17.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.56M Price17.12
Recom1.70 SMA2050.04% SMA5075.18% SMA20011.26% Volume992,660 Change-1.55%
Jun-23-22 07:26PM  
Jun-21-22 08:30AM  
Jun-15-22 02:45PM  
05:41AM  
Jun-14-22 08:00PM  
05:42PM  
05:34PM  
09:05AM  
07:30AM  
Jun-13-22 04:17PM  
07:56AM  
Jun-12-22 05:00PM  
May-23-22 08:30AM  
May-12-22 04:30PM  
May-10-22 04:26PM  
Apr-06-22 08:30AM  
Mar-07-22 07:30AM  
Feb-28-22 04:05PM  
Jan-24-22 04:51AM  
Jan-05-22 08:00AM  
Dec-27-21 10:49AM  
Nov-25-21 04:55AM  
Nov-22-21 07:00AM  
Nov-18-21 08:00AM  
Nov-08-21 04:50PM  
Nov-03-21 08:00AM  
Oct-20-21 09:35AM  
Sep-13-21 07:00AM  
Aug-27-21 07:08AM  
Aug-17-21 07:00AM  
Aug-10-21 04:05PM  
Aug-04-21 08:00AM  
Jul-27-21 07:00AM  
Jun-28-21 04:18PM  
Jun-21-21 09:29AM  
07:00AM  
Jun-01-21 04:01PM  
May-26-21 10:30PM  
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Atlas Venture Opportunity Fund10% OwnerJun 17Buy15.00766,66711,500,005766,667Jun 22 05:09 PM
Gladstone MichaelDirectorJun 17Buy15.00766,66711,500,005766,667Jun 22 04:47 PM
AI Day1 LLC10% OwnerJun 17Buy15.001,200,00018,000,00010,684,638Jun 21 04:37 PM
Blackman Samuel C.Chief Medical OfficerJun 15Sale16.2650,000813,1551,316,718Jun 17 09:47 PM
AI Day1 LLC10% OwnerJan 20Buy14.734,61567,9769,484,638Jan 20 06:37 PM
AI Day1 LLC10% OwnerJan 19Buy14.7058,818864,5669,480,023Jan 20 06:37 PM
AI Day1 LLC10% OwnerJan 18Buy14.2643,429619,3679,421,205Jan 20 06:37 PM
Blackman Samuel C.Chief Medical OfficerJan 03Sale17.1010,000171,0181,366,718Jan 05 08:08 PM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerDec 08Sale18.03110,3381,989,3946,120,124Dec 09 06:04 AM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerDec 07Sale18.76186,9353,507,4756,230,462Dec 09 06:04 AM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerDec 06Sale18.0597,6921,763,3416,417,397Dec 07 06:01 AM
TAKEDA PHARMACEUTICAL CO LTD10% OwnerDec 03Sale18.4712,517231,1896,515,089Dec 07 06:01 AM
Blackman Samuel C.Chief Medical OfficerDec 01Sale17.2210,000172,2421,376,718Dec 03 07:19 PM